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Human papillomavirus (HPV) infection is the main risk factor
for the development of cervical squamous intraepithelial lesions
(SILs) and carcinoma. To date, more than 80 different types of
HPV have been identified and classified as low-risk (e.g. HPV 6,
11, 42, 43, 44) and high-risk (e.g. HPV16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 68) based on their association with SIL and
cervical carcinoma. In particular, HPV 16 is found in only a
small proportion of low-grade SILs but in a much higher propor-
tion of high-grade SILs and invasive squamous carcinomas
(Bosch et al, 1995). 
HPVs are associated with cervical neoplasia through the action
of two of their early (E) proteins, E6 and E7, transcription of
which is regulated by the E2 viral protein through its binding to
sites adjacent to the promoter responsible for this transcription
(Howley et al, 1996; Kovelman et al, 1996). Consequently,
increased expression of E2 results in repression of E6 and E7
expression and vice versa (Dowhanick et al, 1995; Howley et al,
1996). In addition, integration of the viral genome into host DNA,
observed in the majority of cervical carcinomas and less
commonly in pre-invasive lesions, often occurs in the region of the
E1/E2 open reading frames (ORFs) and leads to deletion or disrup-
tion of E1 and/or E2 (Kalantari et al, 1998). Loss of E2 function as
a consequence of integration results in up-regulation of E6/E7
gene transcription and overexpression of E6/E7 proteins leading to
deregulated cell proliferation. 
E2 function can also potentially be altered by gene mutation/
variation. Genomic variation has been extensively studied for
HPV 16-E6 in an attempt to identify naturally occurring variants
that may exhibit altered biological functions (Stoppler et al, 1996;
Zehbe and Tommasimo, 1999). Data examining the E2 gene are
however scanty. In this study, we have investigated specific
sequence variants from the E2 and E6 genes of HPV 16 in low-
and high-grade SILs of the cervix to test the hypothesis that
sequence variation is involved in disease progression. The vari-
ants analysed were chosen from the literature as they are in posi-
tions important for specific biological or immunological
functions. From the hinge region, we analysed the 3410C-T
(P219S), the 3516C-A (T254N) and the 3538A-C (S261-) vari-
ants present in antigenic domains (Gaulthier et al, 1991; 
Terry et al, 1997). From the DNA binding domain we analysed
the 3684C-A (T310K) and the 3694T-A (T313-) variants (Veress
et al, 1999). The first of these variants could be functionally
important given that the DNA-binding activity of E2 is important
for its function. The second allows distinction between the
European variant present in Caski and SiHa cells (3684C-A,
3694prototype) and Asian-American variants (3684C-A and
3694T-A), which contain more widespread variation across the
E2 gene (Casas et al, 1999). From the E6 gene we analysed the
350T-G variant which has been related to viral persistence and
disease progression (Yamada et al, 1995; Londesborough et al,
1996; Zehbe and Tomassimo, 1999). A significant association
was identified between the 3684C-A variant (T310K) in the
DNA-binding domain of E2, but not the other variants analysed,
and lesion grade. Our data suggest that the T310K variant may be
linked to progression from low-to high-grade SILs, in lesions
infected with HPV 16. 
Variation in the E2-binding domain of HPV 16 is
associated with high-grade squamous intraepithelial
lesions of the cervix 
A Giannoudis1, M van Duin2, PJF Snijders2 and CS Herrington1
1University of Liverpool, Department of Pathology, Royal Liverpool University Hospital, Duncan Building, Daulby Street, Liverpool, L69 3GA, UK; 
2University Hospital Vrije Universiteit, Department of Pathology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands 
Summary Human papillomaviruses (HPV) are strongly associated with cervical intraepithelial neoplasia (CIN) and invasive cancer mainly
through the action of the E6 and E7 viral proteins, transcription of which is down-regulated by the E2 protein. To test the hypothesis that HPV
16 E2 variation is important in the development of high-grade squamous neoplasia of the cervix, we carried out a cross-sectional analysis of
low-grade and high-grade squamous intraepithelial lesions (SILs) for specific mutations in the HPV 16 E2 gene and for E2 gene disruption in
these regions. Isolates were also analysed for the HPV 16 350T-G variant. 22 of 178 low-grade SILs and 43 of 61 high-grade SILs examined,
contained HPV 16. No relationship was found between the E6 350T-G variant, or the E2 hinge region 3410C-T variant, and lesion grade.
However, disruption of the regions of E2 analysed was significantly more frequent in high-grade lesions, and there was a significant
association between the 3684C-A variant in the E2 DNA binding domain and high-grade histology suggesting that this variant may be
important in progression to high-grade intraepithelial disease. © 2001 Cancer Research Campaign http://www.bjcancer.com
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MATERIALS AND METHODS 
Tissue specimens 
Tissue specimens from 239 squamous intraepithelial lesions
(SILs) were identified from the diagnostic files of the department
of Pathology, Royal Liverpool University Hospital. The 178 low-
grade SILs comprised condylomata (exophytic and flat) and
cervical intraepithelial neoplasia (CIN) grade 1, the 61 high-grade
SILs comprised CIN grade 3. All of the diagnoses were confirmed
by CS Herrington. Paraffin-embedded archival tissues were used
as sources of DNA. 
DNA extraction 
Three 5 mm formalin-fixed, paraffin sections of cervical biopsy
material were deparaffinized in xylene, washed with 96% ethanol,
pelleted, air-dried and incubated overnight at 55˚C with
200 mg ml–1 proteinase K (Boehringer Mannheim) in 200 mM
Tris-HCl pH 8.0, 1 mM EDTA. The digest was heated to 95˚C
for 20 min to arrest enzyme activity and centrifuged at 13 000 g
for 5 min. The supernatant was used directly in the PCR reaction.
A fragment of the p53 gene (307 bp) was amplified in each case
using the primers p53+ and p53– to ensure the presence of
amplifiable DNA (Giannoudis et al, 1999). 
HPV typing by PCR and hybridization 
15 ml of the extracted DNA were used in a 50 ml PCR reaction. A
140–150 bp fragment from the HPV L1 gene was amplified using
the consensus GP5+/6+ system (Jacobs et al, 1995). 10 ml of the
PCR product were analysed on a 1.7% agarose gel stained with
ethidium bromide. Dot-blot hybridization was carried out using a
5¢ digoxigenin labelled oligonucleotide probe for HPV type 16 as
previously described (Southern et al, 1997). 
PCR amplification of HPV 16-E2 
15 ml of the extracted DNA were used in a 50 ml PCR reaction
containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 200 mM of
each dNTP, 1.5 mM MgCl2, 1 U of Taq DNA polymerase (Gibco)
and 50 pmol of each primer. An initial denaturation step at 94˚C, 1
min and a final extension step at 72˚C, 5 min were performed for
all the PCRs. The conditions of each PCR with the primers, their
position in the E2 gene and the amplified product are summarized
in Table 1A. 
Restriction fragment length polymorphism analysis 
Variants in the E2 gene were identified by RFLP analysis. The
restriction enzyme used for each sequence variant, their recogni-
tion sites and the fragments generated in wild-type and variant
isolates are summarized in Table 1B. 
E2 sequencing 
To confirm the results obtained from RFLP analysis we sequenced
bidirectionally a number of representative samples of variants and
wild-type isolates. All sequencing was performed in an ABI Prism™
373 automated sequencer, using the same primers as for PCR. 
Table 1 (A) PCR conditions with the different primers and their position on the E2 gene. (B) The restriction enzymes
used for RFLP analysis, their recognition sequences and the fragments generated 
(A) 
E2 primers (5¢–3¢) Positions Product Conditions 
Denaturation: 94˚C/1min  A1: GTAATAGTAACACTACACCCATA 3597 
277 bp Annealling: 58˚C/1 min 
A2: GGATGCAGTATCAAGATTTGT 3872  Extension: 72˚C/1 min 
Denaturation: 94˚C/1 min 
B
1: TAGCAGCAACGAAGTATCCTCTCC 3355 
116 bp Annealling: 57˚C/1 min 
B2: TGGATAGTCGTCTGTGTTTCTTCG 3471  Extension: 72˚C/1,5 min 
Denaturation: 94˚C/1 min  C1: CGAAGAAACACAGACGACTATCCA 3448 
203 bp Annealling: 50˚C/1 min 
C2: TAAAGTATTAGCATCACCTT 3649  Extension: 72˚C/1,5 min 
(B) 
E2 mutation Restriction enzyme Recognition site
Restriction fragments 
Wild-type Mutant 
3684C-A Rsa I (Promega) 5¢..GT/AC..3¢ 192+61+24 bp 253+24 
3694T-A Pst I (Promega) 5¢..CTGCA/G..3¢ 177+100 bp 277 bp 
3410C-T Eci I (NEB) 5¢../TCCGCC..3¢ 116 bp 61+55 bp 
3516C-A 116+87 bp 
3538A-C Dde I (Promega) 5¢..C/TNAG..3¢ 115+69+19 bp 134+69 bp1060 A Giannoudis et al 
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Controls 
Amplimers from CaSki cell DNA, which contains 3410C-T and
3684C-A variants, and the HPV 16 plasmid clone (prototype) were
used as controls both in RFLP analysis and sequencing. 
PCR amplification of HPV16-E6 350T/G 
HPV 16 E6 350T/G analysis was performed in 2 independent PCR
reactions using the primers 350-1/350-3, specific for 350G and
350-2/350-3, specific for 350T, as previously described (Van 
Duin et al, 2000). The PCR products were analysed on 1.5%
agarose gels. Southern blot hybridization was carried out using a
[g-32P]ATP 3¢-end labelled oligonucleotide probe at 55˚C (Snijders
et al, 1998). 
Statistics 
The relationships between the different variables were assessed
using Fisher’s exact test. A P value of less than 0.05 was consid-
ered statistically significant. 
RESULTS 
HPV 16 typing 
Using the consensus primers GP5+/GP6+, HPV DNA was identi-
fied in all of the 239 SILs examined. HPV 16 DNA was identified
by PCR and typing in 22/178 (12%) low-grade SILs and 43/61
(70%) high-grade SILs. 
Disruption of the E2 fragments 
In all low-grade SILs amplification was achieved with all of the
primer pairs used. In high-grade SILs failure of amplification was
observed in 6/43 samples using the primers A1–A2, 4/43 using
B1–B2 and 5/43 samples using C1–C2. No isolate showed failure
of amplification of more than one fragment. This failure of ampli-
fication, despite amplification of an internal control with a larger
product size, is consistent with disruption of the E2 gene.
Disruption at these sites was significantly more frequent in high-
grade lesions (15/43, 35%) than in low-grade lesions (0/22, 0%) 
(P = 0.0012, Fisher’s exact test) (Table 2). 
E2 sequence variation 
Sequencing analysis of representative isolates, and of the CaSki
and HPV 16 plasmid products, gave the appropriate sequences. In
the DNA binding domain of E2, the 3684C-A (T310K) variant
(Figure 1A, lanes: 1–4) was identified in 13/38 (34%) high-grade
SILs and 2/22 (9%) low-grade SILs by RFLP (P = 0.03, Fisher’s
exact test). The 3694T-A (T313-) (Figure 1A, lanes: 5–8) variant
was identified in one low-grade SIL: this isolate also carried the
3410C-T, and the 3684C-A variants. None of the isolates from
high-grade SILs contained this sequence variant. 
RFLP analysis of the amplified DNA samples revealed that the
3410C-T variant (P219S) within the hinge region (Figure 1B,
lanes: 4, 5), was present in 27/37 (73%) amplifiable high-grade
SILs and 12/21 (57%) low-grade SILs (P = 0.25, Fisher’s exact
test). Neither the 3516C-A (T254N) nor the 3538A-C (S261-)
(Figure 1B, lanes: 1–3) sequence variant was identified in the 39
amplifiable high-grade SILs or the 21 amplifiable low-grade 
SILs. In one of the 22 low-grade SILs insufficient DNA was 
available to perform analysis of 3410C-T, 3516C-A, or 3538A-C
variants. 
25 of 43 (58%) high-grade SILs contained isolates with either
E2 disruption in the regions analysed or the 3684C-A (T310K)
variant compared with only 2 of 22 (9%) low-grade SILs (P =
0.0001, Fisher’s exact test). 
E6 350T-G analysis 
From the 36 high-grade SILs that gave amplification signal for the
350T-G, 21 (58%) isolates were prototype, 14 (39%) contained 
the 350G variant and 1 (3%) contained both 350T and 350G. 7
samples failed to amplify: this could be due to the incorporation of
an artificial mismatch at the second 3¢ nucleotide position of the
forward primers specific for T or G in order to increase specificity
but failing to achieve the most optimal sensitivity (Snijders et al,
1998). An alternative, albeit unlikely, possibility is that these
samples may contain a base different from T or G. 
9 of 20 (45%) low-grade SILs contained the E6 350T prototype,
7 (35%) contained the 350G variant and 4 (20%) contained both
350T and 350G. In 2 of the 22 samples insufficient material was
available to perform this analysis. 
HPV 16 E6 and E2 variants 
Sequence variation in E2 in combination with the E6 350T-G
variant was identified in 9/14 (64%) and 11/26 (42%) low- and
high-grade SILs respectively (Table 2). The E6 350T-G variants
were compared to both E2 3410C-T and 3684T-A variants in
isolates in which E2 was not disrupted within the relevant region,
and E6 350T-G analysis showed the presence of a single variant
type. The E6 350G variant was present in none of the 12 isolates
with 3410C prototype but was identified in 19/36 isolates with
variant 3410T (P = 0.0013, Fisher’s exact test). The E6 350G
variant was identified in none of the 13 isolates with 3684A
variant but was present in 18/34 isolates with 3684C prototype 
(P = 0.0006, Fisher’s exact test). Thus, the 350G variant segregates
with the 3684C prototype and the 350T prototype segregates with
the 3684A variant. 
DISCUSSION 
In this study we have analysed specific E2 sequence variants in
HPV 16 isolates from low-and high-grade SILs of the cervix. Our
data indicate that (i) the E2 T310K variant segregates with lesion
grade independently of other HPV 16 E6 and E2 variants and, (ii)
the HPV 16 E2 gene is frequently disrupted in the regions analysed
in high-grade SILs but not in low-grade SILs. 
HPV 16 infection is observed in 10–15% of low-grade SILs and
60–90% of high-grade SILs and cervical cancers. Risk factors in
addition to infection have been identified but their exact role in the
development of high-grade lesions and invasive cervical carcin-
oma are not fully elucidated (Southern and Herrington, 1998).
However, expression of the early viral proteins E6, E7 and E2 play
an important role in the disruption of cell cycle control and are
likely therefore to be pivotal in the acquisition by infected cells of
subsequent genetic abnormalities. In particular, as E2 negatively
regulates transcription of the E6 and E7 genes, loss of function of
E2, through either disruption or mutation, leads to up-regulation ofHPV 16-E2 variant in cervical lesions 1061
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Table 2 Summary of results 
No Diagnosis 3410C-T 3516C-A E2 3538A-C 3684C-A 3694T-A E6 350T-G 
1 (S) CIN 1 – – – – – – 
2 (S) CIN 1 T – – A – – 
3 CIN 1 – – – – – – 
4 (S) CIN 1 T – – – – G 
5 CIN 1 – – – – – – 
6 (S) CIN 1 – – – – – – 
7 (S) CIN 1 T – – – – G 
8 (S) CIN 1 T – – – – G 
9 (S) CIN 1 T – – – – G 
10 (S) CIN 1 T – – – – – 
11 CIN 1 – – – – – – 
12 (S) CIN 1 T – – – – –/G 
13 (S) CIN 1 T – – – – G 
14 (S) CIN 1 T – – – – –/G 
15 (S) CIN 1 T – – – – G 
16 CIN 1 – – – – – – 
17 (S) CIN 1 T – – – – G 
18 CIN 1 – – – – – –/G 
19 CIN 1 – – – – – INS 
20 CIN 1 T A – A A – 
21 CIN 1 – – – – – –/G 
22 CIN 1 INS INS INS – – INS 
1 (S) CIN 3 T – – – – – 
2 CIN 3 NA – – A – NA 
3 (S) CIN 3 T – – A – – 
4 (S) CIN 3 – – – – – – 
5 (S) CIN 3 T – – A – – 
6 CIN 3 NA – – – – G 
7 (S) CIN 3 T – – – – G 
8 CIN 3 NA – – – – G 
9 CIN 3 T – – NA NA NA 
10 (S) CIN 3 T – – – – G 
11 (S) CIN 3 – – – – – NA 
12 CIN 3 T NA NA A – – 
13 CIN 3 NA – – – – G 
14 (S) CIN 3 T – – A – – 
15 (S) CIN 3 T – – A – – 
16 CIN 3 T – – A – NA 
17 CIN 3 – NA NA – – NA 
18 (S) CIN 3 T – – A – – 
19 (S) CIN 3 T – – – – G 
20 CIN 3 – – – – – –/G 
21 CIN 3 NA – – – – NA 
22 (S) CIN 3 – – – – – – 
23 CIN 3 T NA NA A – – 
24 (S) CIN 3 T – – – – – 
25 (S) CIN 3 T – – A – – 
26 (S) CIN 3 T – – – – G 
27 CIN 3 – – – – – – 
28 CIN 3 T – – NA NA G 
29 (S) CIN 3 T – – A – – 
30 (S) CIN 3 T – – – – – 
31 CIN 3 – – – – – – 
32 (S) CIN 3 T – – – – G 
33 (S) CIN 3 T – – – – G 
34 CIN 3 T – – NA NA – 
35 (S) CIN 3 T – – – – G 
36 CIN 3 – – – – – NA 
37 (S) CIN 3 – – – A – – 
38 CIN 3 NA – – – – – 
39 (S) CIN 3 T – – A – – 
40 CIN 3 – – – – – – 
41 CIN 3 T NA NA – – G 
42 CIN 3 T – – NA NA G 
43 CIN 3 T – – NA NA G 
NA = Non-amplifiable; INS = insufficient material; (S) = sequenced. 1062 A Giannoudis et al 
British Journal of Cancer (2001) 84(8), 1058–1063 © 2001 Cancer Research Campaign
the HPV early promoter and increased expression of the E6/E7
proteins (Dowhanick et al, 1995; Howley, 1996). 
We identified disruption of one or more of the fragments of 
the E2 gene examined in 35% of high-grade SILs but in none of the
low-grade SILs. These data are consistent with the fact that viral
integration is found more frequently in high-grade SILs and inva-
sive carcinomas than in low-grade SILs. However, E2 disruption is
not a prerequisite for the development of invasive disease. For
example, intact E2 genes have been identified in invasive lesions
where both episomal and integrated viral sequences are present.
Moreover, the presence of an intact E2 gene in some lesions is
consistent with the frequent detection of E2 antibodies in patients
with high-grade SIL and invasive carcinoma (Dillner et al, 1995).
In lesions containing intact E2 genes and expressing E2 protein,
DNA sequence variation with consequent alteration in protein
structure and possibly function may influence both the viral life
cycle and neoplastic transformation. 
In our study, the 3410C-T (P219S) variant, which is in the hinge
region and is close to an antigenic domain (Gaulthier et al, 1991),
was common but not related to lesion grade. Neither the 3516C-A
(T254N) nor the 3538A-C (S261-) variants, both of which are
present within another described antigenic domain (HPV 16
amino-acids 226–275) (Terry et al, 1997) and are within the
sequence of the E4 gene, were identified in the lesions examined. 2
variants in the DNA-binding domain of the E2 gene were also
examined. Variants in this domain could be biologically important
given that the DNA binding activity of E2 is important for its func-
tion. The 3694T-A (T313-) was identified in only one low-grade
SIL that was also carrying the 3410C-T, and the 3684C-A variants.
The 3684C-A (T310K) variant was present in significantly more
isolates from high-grade SILs than in isolates from low-grade
SILs. The T310K substitution is immediately adjacent to the
DNA-binding helix and comparison of prototype and variant
sequences with the crystal structure of the BPV 1 DNA-binding
domain and the NMR structure of the HPV 31 DNA-binding domain
suggests that it may alter the conformation of the E2 protein.
Although a functional study using the T310K variant revealed that
its transactivation properties remain unaltered by comparison with
the prototype (Veress et al, 1999), our data suggest that this substi-
tution may be biologically relevant in vivo. One possible explana-
tion for the differences is that the interaction between cellular
transcription factors, the E2 protein and the viral promoter/
enhancer region may be altered by the T310K variant. This was
not addressed in the published in vitro functional study (Veress 
et al, 1999). 
Finally, we examined the 350T-G (L83V) variant in the HPV 16
E6 gene. This sequence variation has been linked with viral persis-
tence and lesion grade (Londesborough et al, 1996) but additional
studies, conducted in different laboratories, found no association
between its prevalence and lesion grade (Zehbe and Tomassimo,
1999). It has been suggested that the oncogenicity of this specific
E6 variant may vary geographically, possibly due to differences in
the HLA distribution. In our study, the 3684A variant segregated
with the 350T prototype, not the 350G variant. Moreover, there was
no significant difference between the prevalence of the E6 350G
variant in low-and high-grade SILs, in agreement with previous
studies (Zehbe and Tomassimo, 1999), demonstrating that this
segregation was not responsible for the observed relationship
between the 3684C-A variant and CIN 3. It is, however, difficult to
exclude the possibility that other variants, which may co-segregate
with this E2 variant, might be related to the observed clinical effect.
The identification of both E6 350T and 350G in some lesions is
consistent with a recent study in which the same phenomenon was
reported (Emeny et al, 1999). It is of note that dual infection was
present in a greater number of low-grade SILs than high-grade
SILs. Although the number of lesions analysed is small, this obser-
vation is consistent with the decrease in prevalence of infection
with multiple HPV types with increasing severity of cervical
neoplasia (Chang et al, 1997). The biological significance of infec-
tion with multiple HPV variants remains to be determined. 
In summary, no relationship was found between the E6 350T-G
variant, or the E2 hinge region 3410C-T variant, and lesion 
grade. However, disruption of the regions of E2 analysed was signi-
ficantly more frequent in high-grade lesions, and there was a
significant association between the 3684C-A (T310K) variant in
the E2 DNA-binding domain and high-grade histology. In addi-
tion, the 350T-G variant segregated with the 3410C-T but not 
with the 3684C-A variant indicating that the biological effect of
3684C-A is not a surrogate marker of 350T-G. These findings
suggest that infection with HPV 16 variants containing the 3684C-A
variant may be important in progression to high-grade intraepi-
thelial disease. 
253 bp
192 bp 
61 bp
1234M5678 123 M45
116 bp
61 bp
59 bp
115 bp 277 bp
177 bp 
100 bp
69 bp
AB
Figure 1 Restriction fragment length polymorphism analysis. The plasmid pBR322 digested with Msp I was used as molecular size marker (M). (A) Lanes
1–4: PCR products digested with Rsa I. Wild type E2 (lanes 1, 3) giving 192, 61 and 24 bp (not visible) fragments. T310K variant (lanes 2, 4) giving 253 and
24 bp fragments. Lanes 5–8: PCR products digested with Pst I. Wild-type E2 (lanes 5–7) giving 177 and 100 bp fragments. T313- (lane 8) loses the restriction
site, giving full length PCR product. (B) Lanes 1–3: PCR products digested with Dde I showing wild-type E2 giving 115, 69 and 19 bp (not visible) fragments.
Lanes 4–5: PCR products digested with Eci I. Wild-type E2 (lane 5) giving 116 bp fragment. P219S variant (lane 4) giving 61 and 55 bp fragments HPV 16-E2 variant in cervical lesions 1063
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